A new paradigm for T2DM care in the era of SGLT-2i

01 Oct 2021
Dapagliflozin excels in chronic kidney disease, even in patients without diabetes
During the recent EMPIRE SUMMIT, Professor Dr Chee Kok Han discussed the importance of an early, patient-centred,multi factorial approach in managing type 2 diabetes mellitus(T2DM). Specifically, Professor Chee highlighted the role ofempagliflozin (Jardiance®, Boehringer Ingelheim) in conferring cardiorenal protection to patients with T2DM.

Related MIMS Drugs

Editor's Recommendations